

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 10/12/2006

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/787,079	03/07/2001	Jorg Rosenberg	0480/001216	1470
26474	7590 10/12/2006		EXAM	INER
	RUCE DELUCA & QUI	HUSON, MONICA ANNE		
1300 EYE STREET NW SUITE 400 EAST TOWER WASHINGTON, DC 20005			ART UNIT	PAPER NUMBER
			1732	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
		09/787,079	ROSENBERG ET AL.
Office Action Summary		Examiner	Art Unit
		Monica A. Huson	1732
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet w	with the correspondence address
A SH WHIC - Exte after - If NC - Failu Any	IORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DAMES and the may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Of period for reply is specified above, the maximum statutory period we are to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing led patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUN 36(a). In no event, however, may a vill apply and will expire SIX (6) MO cause the application to become a	IICATION. a reply be timely filed DNTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).
Status			
	This action is FINAL . 2b) This Since this application is in condition for allowar	action is non-final.	·
	closed in accordance with the practice under E	x parte Quayle, 1955 C.	D. 11, 453 O.G. 213.
4)⊠ 5)□ 6)⊠ 7)□ 8)□ Applicati 9)□ 10)⊠	Claim(s) 1-5,7-9,11 and 12 is/are pending in the 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) 1-5,7-9,11 and 12 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or ion Papers The specification is objected to by the Examiner The drawing(s) filed on 07 March 2001 is/are: a Applicant may not request that any objection to the or Replacement drawing sheet(s) including the correction The oath or declaration is objected to by the Examiner The Oath Oath Oath Oath Oath Oath Oath Oath	vn from consideration. relection requirement. r. a)⊠ accepted or b)□ of drawing(s) be held in abeya on is required if the drawing.	ance. See 37 CFR 1.85(a). g(s) is objected to. See 37 CFR 1.121(d).
12)⊠ a)[Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prioric application from the International Bureau See the attached detailed Office action for a list of	s have been received. s have been received in a ity documents have been (PCT Rule 17.2(a)).	Application No n received in this National Stage
2)	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	Paper No	Summary (PTO-413) (s)/Mail Date Informal Patent Application

Application/Control Number: 09/787,079

Art Unit: 1732

DETAILED ACTION

This office action is in response to the paper filed 17 July 2006.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless – (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-3, 5, 7-9, 11, and 12 are rejected under 35 U.S.C. 102(b) as being anticipated by Dabal et al. (U.S. Patent 4,072,551). Regarding Claim 1, Dabal et al., hereafter "Dabal," show that it is known to carry out a method for producing tablets by melt extrusion (Column 8, lines 1-44; Column 10, lines 3-13), in which an extrudable pharmaceutical mixture is heated and extruded in the form of a continuous product strip, wherein, in a first stage, the still deformable product strip is compressed to a continuous tablet belt, the individual tablets in the belt being connected together by product webs (Figure 5, element 82, 83), in a second stage, downstream of the first stage, the tablet belt is allowed to cool to form a solidified tablet belt (Figure 5, printing unit; It is noted that ambient cooling will take place along the transport sections.), in a third stage, downstream of the second stage, the tablets are mechanically singulated in a continuous process (Figure 5, unitizing unit), and then the singulated tablets are transported further to a fourth stage downstream of the said third stage where the singulated tablets are subsequently deflashed (Column 32, lines 13-18).

Regarding Claim 2, Dabal shows the process as claimed as discussed in the rejection of Claim 1 above, including a method wherein a force with a component perpendicular to the plane of the tablet belt is allowed to act on the tablet belt for singulation of the tablet (Figure 5, unitizing unit; It is noted that the force exerted by the roller will have at least two components.).

Regarding Claim 3, Dabal shows the process as claimed as discussed in the rejection of Claim 2 above, including a method wherein a force with a component parallel to the plane of the tablet belt is allowed to act on the tablet belt for singulation of the tablets (Figure 5, unitizing unit; It is noted that the force exerted by the roller will have at least two components.).

Regarding Claim 5, Dabal shows the process as claimed as discussed in the rejection of Claim 3 above, including a method wherein the parallel force component is generated by exerting a traction force on the solidified tablet belt (Figure 5, unitizing unit; It is noted that the force exerted by the rollers will include some traction force.).

Regarding Claim 12, Dabal shows that it is known to have an apparatus for producing tablets (Figure 5), comprising at least one extruder means for heating a pharmaceutical mixture (Column 8, lines 1-44; Column 10, lines 3-13); means for shaping a tablet belt from said extruded heated pharmaceutical mixture arranged downstream of said extruder (Figure 5, element 82, 83); first transport means for said tablet belt comprising means for cooling the extruded tablet belts and which is arranged downstream of said shaping means (Figure 5, printing unit; It is noted that ambient cooling will take place along the transport sections.), and means for singulating and deflashing said tablets, wherein said means for singulating and deflashing said tablets comprise at least one singulating means arranged downstream of said first transport means and at least one deflashing means arranged downstream of said singulating means and spatially separate therefrom (Figure 5, unitizing unit; Column 32, lines 13-18; It is noted that the transport means is the tension force that is generated by the two rollers acting together on the tablet belt.).

Application/Control Number: 09/787,079

Art Unit: 1732

Regarding Claim 7, Dabal shows the apparatus as claimed as discussed in the rejection of Claim 12 above, including a machine wherein the singulating means comprises at least one rotatable roller (Figure 5, unitizing unit).

Regarding Claim 8, Dabal shows the apparatus as claimed as discussed in the rejection of Claim 7 above, including a machine wherein the singulating means comprises two counter-rotating rollers which can be pressed against one another (Figure 5, unitizing unit).

Regarding Claim 9, Dabal shows the apparatus as claimed as discussed in the rejection of Claim 12 above, including a machine wherein the singulating means comprises at least one embossed roller (Column 22, lines 58-63).

Regarding Claim 11, Dabal shows the apparatus as claimed as discussed in the rejection of Claim 12 above, including a machine wherein a second transport means is provided between the singulating means and the deflashing means comprises a shaking or vibrating unit (Column 30, lines 12-19; Column 32, lines 13-18; It is noted that by suggesting that the tablets are amenable to online testing throughout their production, Dabal implies that the tablets are transported from the unitizing to the deflashing operation in a predetermined fashion.).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claim 4 is rejected under 35 U.S.C. 103(a) as being unpatentable over Dabal, in view of Klimesch et al. (U.S. Patent 5,073,379). Dabal shows the process as claimed as discussed in the rejection of Claims 1 and 2 above, but

Art Unit: 1732

he does not show a directional force that diverts the tablet belt in a specific direction. Klimesch '379 shows that it is known to carry out a method wherein the perpendicular force component is generated by diverting the solidified tablet belt out of its transport plane (Figure 1; Column 2, lines 61-67). It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to use Klimesch '379's diverting force to tabulate Dabal's belt in order to most efficiently achieve the unitizing operation.

Response to Arguments

Applicant's arguments filed 17 July 2006 have been fully considered but they are not persuasive.

Applicant contends that Dabal does not show the instant invention because he does not show extruding a pharmaceutical mixuture in the form of a continuous product strip. Applicant appears to imply that a pharmaceutical mixture necessarily requires an active ingredient. This is not persuasive because the claim does not exclusively require extruding a mixture containing an active ingredient, and it is maintained that Dabal's extruded mixture does contain pharmaceutical ingredients (Column 8, lines 35-50). Although Dabal's active ingredient is not extruded with the product web, it is maintained that he nevertheless extrudes a pharmaceutical mixture.

Applicant contends that Dabal does not show the instant invention because he does not show, in a first stage, compressing the still deformable product strip to a continuous tablet belt. This is not persuasive because Dabal shows this limitation in Figure 5, elements 82, 83, and 85.

Applicant contends that Dabal does not show the instant invention because he does not show allowing the tablet belt to cool to form a solidified tablet belt. Applicant disagrees with the examiner that transport of the belt among the processing stations will allow for ambient cooling. The examiner maintains her rejections and points to US 4,692,199 to support the assertion

Page 6

Art Unit: 1732

that ambient cooling occurs during passage of an article through ambient conditions (Abstract) (e.g. from a processing station to a final station).

Applicant contends that Dabal does not show the instant invention because he does not show a force with a component perpendicular to the plane of the tablet belt for singulation of the tablets. This is not persuasive because Dabal shows this limitation as his Rotary Unitizing element. With respect to claim 7, the phrase "for diverting the tablet belt out of a transport plane" has been interpreted as only an intended use or consequence of the positively-recited method claims.

Applicant has not specifically argued the rejections made under 35 USC 103.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Monica A. Huson whose telephone number is 571-272-1198. The examiner can normally be reached on Monday-Friday 7:30am-4:00pm.

Art Unit: 1732

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Johnson can be reached on 571-272-1176. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Monica A Huson

October 2, 2006

CHRISTINA JOHNSON PRINARY EXAMINER

10/404

Page 7